Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

NCT03806049 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of financial support

Conditions

Ovarian Cancer

Interventions

DRUG: Niraparib
DRUG: Bevacizumab
DRUG: TSR042
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Nordic Society of Gynaecological Oncology - Clinical Trials Unit